Evidence map›Paper›PMID 42252764›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2026

Multivalent Aptamers: Contemporary Engineering Strategies and Biomedical Applications.

Chengliang Liu, Zhijun Tang, Yilin Zhu, Xuanrong Sun, Lujuan Xu, Xiangsheng Liu

Abstract readReview
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chengliang LiuCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Zhijun TangCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Yilin ZhuCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Xuanrong SunCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.ORCID https://orcid.org/0000-0001-5414-9300
Lujuan XuThe Key Laboratory of Zhejiang Province For Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Xiangsheng LiuThe Key Laboratory of Zhejiang Province For Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

Funding

National Natural Science Foundation of China 22304181The "Pioneer" and "Leading Goose" R&D Program of Zhejiang 2024DYXS0001The "Pioneer" and "Leading Goose" R&D Program of Zhejiang 2025C01109Zhejiang Provincial Natural Science Foundation of China LQKHM26B0202 LDQ24B020002
6 · The paper itself

Abstract

Nucleic acid aptamers represent a distinctive class of molecular recognition elements with high binding affinity, excellent chemical stability, and low immunogenicity, making them powerful tools for diverse biomedical applications. Nevertheless, monovalent aptamers are often constrained by limited binding avidity, suboptimal pharmacokinetics, and insufficient biological activation. To address these challenges, multivalent aptamers engineered by assembling multiple units in a well-defined spatial configuration, have emerged to significantly enhance target engagement. This approach improves affinity, specificity, and functional potency, unlocking novel applications inaccessible to monovalent constructs. This review provides a comprehensive overview of recent advances in multivalent aptamer engineering. First, we outline advancements in systematic evolution of ligands by exponential enrichment (SELEX) strategies enabling the direct evolution of multivalent aptamers through rational library design and target-guided selection. Subsequently, we discuss various design approaches for constructing multivalent architectures, alongside their advantages and limitations. Finally, we highlight representative applications, including targeted delivery, therapeutic intervention, molecular imaging, and diagnostics, which capitalize on the multivalency effect to achieve superior biological outcomes in next-generation biomedicine.

Indexed as

Aptamers, NucleotideAnimalsDrug Delivery SystemsHumansSELEX Aptamer TechniqueAptamers, NucleotideDNA nanotechnologymultivalency effectmultivalent aptamersprecision therapeuticsSELEXtargeted drug delivery

Identifiers

PMID42252764
PMCPMC13392793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.